New hope for tough blood cancers: experimental combo enters human trials
NCT ID NCT07294677
Summary
This study is testing whether adding a new drug called capivasertib to standard chemotherapy works better for adults with acute leukemia or lymphoblastic lymphoma. Researchers will first find the safest dose, then test if the combination helps patients achieve remission with no detectable cancer cells. The trial is for adults whose cancer has returned or didn't respond to treatment, or for newly diagnosed patients over 40.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.